Efikasi Terapi Topikal Kortikosteroid Ultrapoten, Solusio, dan Gel Timolol Maleat 0,5% Terhadap Hemangioma Infantil Superfisial
Sari
Latar belakang. Terapi kortikosteroid ultrapoten menjadi terapi topikal standar untuk HI. Namun, kortikosteroid banyak efek
samping dan respon yang kadang gagal, perlu alternatif terapi topikal lain. Solusio dan gel timolol maleat 0,5% merupakan beta
bloker non selektif yang ternyata dapat menghambat proliferasi dan memicu regresi HI.
Tujuan. Mengetahui efikasi terapi kortikosteroid topikal ultrapoten, solusio, dan gel timolol maleat 0,5% pada hemangioma infantil
superfisial.
Metode. Desain penelitian kohort retrospektif, dilibatkan 79 pasien HI superfisial dalam kurun waktu Januari 2011-Oktober 2015
di RSUP. Dr. Sardjito, Yogyakarta.
Hasil. Perbandingan selisih luas antara ketiga kelompok didapatkan perbedaan yang bermakna antara solusio timolol maleat 0,5%
dibandingkan kortikosteroid ultrapoten 0,5% (p<0,001). Gel timolol maleat 0,5% dibandingkan kortikosteroid ultrapoten (p<0,001).
Perbandingan antara selisih luas lesi setelah terapi solusio dan gel timolol maleat 0,5% tidak berbeda secara bermakna (p=0,744).
Kesimpulan. Efikasi solusio dan gel timolol maleat 0,5% lebih baik dibandingkan kortikosteroid topikal ultrapoten terhadap
pengurangan luas lesi hemangioma infantil superfisial.
Kata Kunci
Teks Lengkap:
PDFReferensi
Frieden IJ. Infantile hemangioma research: Looking
backward and forward. J Invest Dermatol 2011;131:
-8.
Callahan A, Yoon M. Infantile hemangioma : A review.
Saudi J Ophthal 2012;26:283-91.
Rosenblatt A, Mathes EF, Rosbe KW. Infantile
hemangiomas: From pathogenesis to clinical features.
Research Rep Neonat 2012;2:55-64.
Pope E, Krafchik BR, Macarthur C, Stempak D,
Stephens D, Weinstein M, Baruchel S. Oral versus
high-dose pulse corticosteroids for problematic infantile
hemangiomas: A randomized, controlled trial. Pediatrics
;119:e1239-47.
Pandey A, Gangopadhyay AN, Sharma SP, Kumar V,
Gupta DK, Gopal SC. Evaluation of topical steroids
in the treatment of superficial hemangioma. Skinmed
;8: 9-11.
Barnes CM, Christison-Lagay EA, Folkman J. The
placenta theory and the origin of infantile hemangioma.
Lymphat Res Biol 2007;5:245-55.
Bischoff J. Progenitor cells in infantile hemangioma. J
Craniofac Surg 2009;20:Suppl 1:695-7.
Boscolo E, Bischoff J. Vasculogenesis in infantile
hemangioma. Angiogenesis 2009;12:197-207.
Boye E, Jinnin M, Olsen BR. Infantile hemangioma:Challenges, new insights, and theraupetic promise. J
Craniofac Surg 2009;20:Suppl 1:678-84.
Leaute-Labreze C, Taieb A. Efficaccy of beta-blocker in
infantile capilarry haemangiomas: The physiopathological
significance and therapeutic consequences. Ann
Dermatol Venereol 2008;135:860-2.
Pope E, Chakkitakandiyil A. Topical timolol gel for
infantile hemangiomas: A pilot study. Arch Dermatol
;146:564-5.
Calvo M, Garcia-Millan C, Villegas C, Fueyo-Casado
A, Buron I. Topical timolol for infantile hemangioma of
the eyelid. Int J Dermatol 2012;52:603-4.
Chakkittakandiyil A, Phillips R, Frieden IJ, Siegfried
E, Lara-Corrales I, Lam J, Bergmann J, Bekhor P,
Poorsattar S, Pope E. Timolol maleate 0.5% or 0.1%
gel-forming solution for infantile hemangiomas: A
retrospective multicenter, cohort study. Pediatr Dermatol
;29:28-31.
Bonifazi E, Milano A, Colonna V. Evaluation of safety
and efficacy of a galenic preparation of 1% propranolol
in 89 cases of cutaneous infantile hemangioma. Eur J
Pediatr Dermatol 2013;23:93-104.
Ricciatti-Sibbald D, Sibbald RG. Dermatologic vehicles.
Clin Dermatol 1989;7:11
Souza AD, Strober BE. Principles of topical therapy.
Dalam: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS,
Leffell DJ, Wolff K, penyunting Fitzpatrick’s dermatology
in general medicine. Edisi ke-8. New York: McGraw-Hill
Copanies; 2012.h.2643-51.
Gorincour G, Kokta V, Rypens F, Garel L, Powell
J, Dubois J. Imaging characteristics of two subtypes
of congenital hemangiomas: Rapidly involuting
congenital hemangiomas and non-involuting congenital
hemangiomas. Pediatr Radiol 2005;35:1178-85.
Bree AF, Siegfried E, Sotelo-Avila C, Nahass G. Infantile
hemangiomas: Speculation on placental trophoblastic
origin. Arch Dermatol 2001;137:573-7.
Ho NT, Lansang P, Pope E. Topical imiquimod in the
treatment of infantile hemangiomas: A retrospective
study. J Am Acad Dermatol 2007;56:63-8.
Abarzua-Araya A, Navarrete-Dechent CP, Heusser
F, Retamal J, Zegpi-Trueba MS. Atenolol versus
propranolol for the treatment of infantile hemangiomas:
A randomized controlled study. J Am Acad Dermatol
;70:1045-9.
Ariwibowo L, Radiono S, Danarti R. Evaluasi terapi
kortikosteroid topikal ultrapoten dan solusio timolol
maleat 0,5% terhadap ukuran hemangioma infantil
superfisial, tesis. Universitas Gadjah Mada, 2015.
Ariwibowo L, Danarti R. Comparison of efficacy
between topical corticosteroid, timolol maleat 0,5%
eye drop, and education observation in managing
infantile hemangioma. Oral presentation. 21st Regional
Conference of Dermatology. Danang Vietnam 9-12
April. 2014:(abstract book p. 189-90).
Greenberger S, Boscolo E, Adini I. Corticosteroid
suppression of VEGF-A in infantile hemangioma-derived
stem cells. N Engl J Med 2010;362 1005-13.
Theletsane T, Redfern A, Raynham O, Harris T,
Prose NS, Khumalo NP. Life-threatening infantile haemangioma: A dramatic response to propranolol. J
Eur Acad Dermatol Venereol 2009;23:1465-6.
Peridis S, Pilgrim G, Athanasopoulos I, Parpounas K.
A meta-analysis on the effectiveness of propranolol for
the treatment of infantile airway haemangiomas. Int J
Pediatr Otorhinolaryngol 2011;75:455-60.
Valencia IC, Kerdel FA. Topical corticosteroids. Dalam:
Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell
DJ, Wolff K, penyunting. Fitzpatrick’s dermatology in
general medicine. Edisi ke-8. New York: McGraw Hill
Companies; 2012.h.2659-65.
DOI: http://dx.doi.org/10.14238/sp17.6.2016.428-34
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.